Literature DB >> 15864685

Immune thrombocytopenic purpura associated with rheumatoid arthritis: case report.

Taro Horino1, Atsushi Sasaoka, Toshihiro Takao, Takafumi Taguchi, Hiroshi Maruyama, Hiroyuki Ito, Shigeki Takemoto, Hirokuni Taguchi, Kozo Hashimoto.   

Abstract

A 54-year-old Japanese woman was diagnosed with rheumatoid arthritis (RA) in 1995 on the basis of symmetric effusive polyarthritis, morning stiffness, and strongly positive rheumatoid factor. She had received low-dose prednisolone, indomethacin, methotrexate (MTX), and cyclophosphamide (CPA), at least, over 4 years before the current admission and showed partial improvement of polyarthralgia. In November 2002, she suddenly developed thrombocytopenia (platelet count was 0.3 x 10(4) mm(-3)) with purpura and was diagnosed with immune thrombocytopenic purpura (ITP). As she had refractory ITP, the administration of pulsed high-dose dexamethasone (DEX) therapy was started, resulting in the complete remission of ITP. The present paper reports that pulsed high-dose DEX therapy was useful for the treatment of refractory ITP associated with RA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864685     DOI: 10.1007/s10067-005-1113-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  Immune thrombocytopenic purpura.

Authors:  Issa Khouri; Bertrand Tuan; Kathleen Grant
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.

Authors:  Yunfeng Cheng; Raymond S M Wong; Yannie O Y Soo; Chung Hin Chui; Fung Yi Lau; Natalie P H Chan; Wai Shan Wong; Gregory Cheng
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

3.  High-dose dexamethasone in adult refractory idiopathic thrombocytopenic purpura.

Authors:  C Schiavotto; M Ruggeri; G Castaman; F Rodeghiero
Journal:  Br J Haematol       Date:  1996-05       Impact factor: 6.998

4.  High-dose pulsed dexamethasone for immune thrombocytopenia.

Authors:  H Demiroğlu; S Dündar
Journal:  N Engl J Med       Date:  1997-08-07       Impact factor: 91.245

5.  A case report of a patient who has pure red cell aplasia and rheumatoid arthritis.

Authors:  C Ustün; D Karavelioğlu; O Ilhan; O Aydintuğ; M Beksaç
Journal:  Int J Hematol       Date:  1997-12       Impact factor: 2.490

6.  Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura.

Authors:  R Stasi; M Brunetti; A Pagano; E Stipa; M Masi; S Amadori
Journal:  Blood Cells Mol Dis       Date:  2000-12       Impact factor: 3.039

7.  Autoimmune hemolytic anemia and rheumatoid arthritis.

Authors:  C A Estrada; S Lyons; H Terebelo
Journal:  South Med J       Date:  1990-05       Impact factor: 0.954

8.  Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura.

Authors:  Yasser A Wali; Zakia Al Lamki; Wasifuddin Shah; Mathew Zacharia; Ahmed Hassan
Journal:  Pediatr Hematol Oncol       Date:  2002 Jul-Aug       Impact factor: 1.969

9.  Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia.

Authors:  F M Balis; C M Lester; G P Chrousos; R L Heideman; D G Poplack
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

10.  High-dose oral dexamethasone therapy for chronic childhood idiopathic thrombocytopenic purpura.

Authors:  D M Adams; T R Kinney; E O'Branski-Rupp; R E Ware
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

View more
  2 in total

1.  Methorexate therapy in a patient with rheumatoid arthritis complicated by idiopathic thrombocytopenic purpura.

Authors:  Sabiha Komoğlu; Duygu Silte; Meltem Sertbaş; Yaşar Sertbaş; Ali Özdemir
Journal:  Eur J Rheumatol       Date:  2015-03-01

2.  Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report.

Authors:  Naidan Zhang; Chaixia Ji; Xiao Bao; Chengliang Yuan
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.